Board Certified, American Board of Ophthalmology
Dr. Sundstrom's research program focuses on the development of biomarkers and novel therapeutic targets for age-related macular degeneration (AMD), the leading cause of legal blindness in the United States. In 2006, intravitreal injection of anti-VEGF antibodies were shown to improve vision in patients with neovascular AMD. Although this intervention has revolutionized the treatment of AMD, less than half of the patients respond with modest improvements visual acuity and no treatment exists for non-exudative AMD. Dr. Sundstrom has developed a deep proteomics assay capable of identifying retinal derived proteins from clinical vitreous samples. Comparative vitreous proteomic studies are ongoing in an effort to identify proteins associated with end-stage neovascular and non-exudative AMD. Preclinical research will subsequently be conducted to validate these newly identified biomarkers and/or therapeutic targets. Dr. Sundstrom's educational responsibilities include mentoring medical students for the Medical Student Research project as well as teaching Ophthalmology residents both in the clinic and through a monthly Retina Imaging Conference.
We accept a variety of health insurance plans and will submit claims on your behalf. Certain coverage restrictions may apply based on your individual benefit package.
Medical School, Penn State College of Medicine - 2008
Fellowship, Medical Retina University of Michigan Medical School (Ann Arbor) - 2013
Residency, Ophthalmology Milton S. Hershey Medical Center - 2012
Internship, Medicine Milton S. Hershey Medical Center - 2009
- Development of biomarkers and novel therapeutic targets for age-related macular degeneration (AMD), the leading cause of legal blindness in the United States.
- American Ophthalmological Society Travel Grant, 2013
- Heed Fellowship, 2012